Research Reports published by KHAMBATTA SECURITIES

Name: Latest research reports of Krsnaa Diagnostics Ltd. authored by Khambatta Securities and published by - Trendlyne research reports.
Item: Krsnaa Diagnostics Ltd.
Rating: 5
Author: Khambatta Securities

Latest research reports published by Khambatta Securities

Krsnaa Diagnostics Ltd.

19 Feb 2025

749.85

1.32%

Maintaining a positive outlook whilst addressing short-term headwinds

Buy: Krsnaa Diagnostics Ltd.

Recommendation Target

Khambatta Securities

Krsnaa Diagnostics Limited’s (KDL’s) revenue decreased due to seasonal
factors and temporary operational issues. The Mumbai BMC project ended
earlier than expected, and the Maharashtra city and Madhya Pradesh MRI
installations experienced delays due to site handover issues which led to a
temporary dip in revenues.

Krsnaa Diagnostics Ltd. has gained 25.36% in the last 1 Year

Varroc Engineering Ltd.

18 Feb 2025

407.10

1.55%

Strong order book boosts earnings outlook

Buy: Varroc Engineering Ltd.

Target

Khambatta Securities

Varroc Engineering reported healthy revenue growth of 10.1% y-o-y in 3QFY25. This was driven primarily by a strong showing by the company’s India business, which achieved 9.5% growth despite headwinds in the 2W, 3W and PV markets.

Varroc Engineering Ltd. has lost -32.53% in the last 3 Months

Century Plyboards (India) Ltd.

17 Feb 2025

696.90

2.22%

Current valuations discount expansion plans

Hold: Century Plyboards (India) ...

Target

Khambatta Securities

Century Plyboards (India) Limited (CPIL) reported robust revenue of Rs 1,140.5 crore (+21.7% y-o-y) in 3Q FY25, driven by volume expansion in MDF (+19.0% y-o-y) and Plywood (+16.0% y-o-y). The Particle Board (1.2% y-o-y) and Laminates (-9.4% y-o-y) segments witnessed volume de-growth.

Century Plyboards (India) Ltd. has lost -22.99% in the last 6 Months

Krishna Institute of Medical Sciences Ltd.

11 Feb 2025

616.75

3.80%

Current valuations discount near-term earnings growth

Hold: Krishna Institute of Medic...

Recommendation Target

Khambatta Securities

? Krishna Institute of Medical Sciences (KIMS) reported a robust 29.7% y-o-y increase in total income to Rs 790.2 crore in 3Q FY25.
? Calculated blended occupancy rate (basis total bed capacity) was 50.7% in 3Q FY25, compared to 56.8% in 2Q FY25.

Krishna Institute of Medical Sciences Ltd. is trading above all available SMAs

Prataap Snacks Ltd.

07 Feb 2025

1163.55

8.16%

Temporarily suspending coverage due to management’s inability to offer visibility

Not Rated: Prataap Snacks Ltd.

Khambatta Securities

Raw material costs, especially for palm oil and potatoes, continued to rise in the third quarter as expected. The reinstatement of import duties on crude and refined palm oil exacerbated the RM cost issue and its consequent impact on margins.

Prataap Snacks Ltd. is trading above all available SMAs

Subros Ltd.

05 Feb 2025

570.30

1.70%

Focus on localization and future technologies amid industry slowdown

Buy: Subros Ltd.

Target

Khambatta Securities

Subros reported a revenue growth of 12.1% y-o-y in 3Q FY25, while 9MFY25 sales increased 9.8% y-o-y, led by higher volume and Start of Production (SOP) of a new business award. Quarterly EBITDA increased 27.4% y-o-y while EBITDA margin expanded 111 bps to 9.2%.

Subros Ltd. has an average target of 799.00 from 1 broker.

EFC (I) Ltd.

04 Feb 2025

230.65

7.63%

FY25 growth guidance cut; valuations attractive

Buy: EFC (I) Ltd.

Target

Khambatta Securities

EFC reported modest results in 3Q FY25. The company has lowered its revenue growth forecast for FY25 from a potential doubling of FY24 revenue to a more conservative target of at least 50% growth.

EFC (I) Ltd. is trading below its 50 day SMA of 235.0

Home First Finance Company India Ltd.

30 Jan 2025

1059.00

1.00%

Strong growth in disbursals continue to drive AUM and revenues

Buy: Home First Finance Company...

Target

Khambatta Securities

Home First Finance Company (HFFC) reported robust 3Q FY25 results driven by continued growth in disbursals (Rs 1,193 crore, +18.4% y-o-y, +1.4% q-o-q). AUM reached Rs 11,945 crore (+32.6% y-o-y, +6.4% q-o-q).

Home First Finance C.. has an average target of 1213.75 from 4 brokers.

Emami Ltd.

29 Jan 2025

608.50

1.44%

Headwinds mar outlook visibility

Buy: Emami Ltd.

Target

Khambatta Securities

Emami’s reported moderate sales growth in 3Q FY25, encountering economic and industry headwinds. Urban demand remained subdued due to rising food inflation and cash-strapped retail and wholesale trade.

Number of FII/FPI investors increased from 328 to 346 in Dec 2024 qtr.

Sharda Cropchem Ltd.

27 Jan 2025

494.75

8.49%

Volume fuels revenue, continued price recovery uplifts outlook

Buy: Sharda Cropchem Ltd.

Recommendation Target

Khambatta Securities

? Sharda Cropchem Limited (SCL) reported solid growth in 3Q FY25 as revenues increased by 46.9% y-o-y to Rs 929.3 crore, fuelled by a robust increase in sales volume and a strategic price adjustment. Growth was observed across regions, with Europe and North America exhibiting
strong performance.
? Gross margin expanded by 650 bps y-o-y to 32.7%.

Sharda Cropchem Ltd. has gained 30.96% in the last 1 Year